NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Nautilus Biotechnology, Inc. (NAUT) Stock Analysis

Nautilus Biotechnology, Inc. (NAUT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

NAUT

$0.91

−$0.02 (−1.63%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NAUT with… →

NAUT Key Statistics

As of Sep 4, 2026
Trading
Open
$0.91
Previous Close
$0.92
Day's Range
0.89–0.95
52-Week Range
0.65–4.31
Volume
576.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.87
Valuation
Market Cap
$115.15M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
606.07
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.44
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$59.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
127.26M
1-Year Return
+38.80%
Dividend and dates
Earnings Date
October 27, 2026estimated
Avg Volume
885.81K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NAUT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−53.59%
2025+16.07%
2024−43.81%
2023+66.11%
2022−65.25%
2021−52.26%
2020 (partial year)+3.93%

As of September 4, 2026.

NAUT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$59.00M—
2024$0.00−$70.78M—
2023$0.00−$63.68M—
2022$0.00−$57.92M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$66.84M−$59.00M—
2024$0.00—−$81.48M−$70.78M—
2023$0.00—−$76.15M−$63.68M—
2022$0.00—−$63.62M−$57.92M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NAUT Valuation vs Biotechnology Median

Median of 656 stocks
MetricNAUTBiotechnology medianvs median
P/S ratio606.0715.2639.7x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Nautilus Biotechnology, Inc. (NAUT) at $115.15M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 127.

The most recent close on file for NAUT is $0.91, dated September 4, 2026. That is −$0.02 (−1.63%) against the previous close. The 52-week range on file runs from $0.65 to $4.31. The latest close sits 38.8% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $59.00M. Profit margin runs at 0%. Trailing earnings per share are −0.44.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 606.07. On price-to-sales that is 39.7 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.87. Daily returns over the trailing 6 years annualize to a volatility of 86.97%. Over the trailing twelve months the price has returned +38.80%. Measured over 5 years, that is −34.82% a year compounded.

Growth & Income

The record shows no dividend for NAUT.

2026 is still running; the price is −53.59% year to date. Across the complete calendar years on file, 2023 returned +66.11% and 2022 returned −65.25%. Of the 5 complete calendar years on file, 2 finished higher.

Peer Comparison

Nautilus Biotechnology, Inc. (NAUT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Nautilus Biotechnology, Inc. NAUT $115.15M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Nautilus Biotechnology, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Visit website →